Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 1–8 of 8 records
Inclisiran (Leqvio)
RNA-silencing medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
High LDL cholesterol that stays high despite statins
Givosiran (Givlaari)
RNA-silencing medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Acute porphyria attacks — severe abdominal pain crises
Lumasiran (Oxlumo)
RNA-silencing medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Primary hyperoxaluria type 1 — a genetic cause of kidney stones and kidney failure
Nedosiran (Rivfloza)
RNA-silencing medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Primary hyperoxaluria type 1 — a genetic cause of kidney stones and kidney failure
Patisiran (Onpattro)
RNA-silencing medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Nerve damage caused by inherited transthyretin amyloidosis
Fitusiran (Qfitlia)
RNA-silencing medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Haemophilia A or B, including when factor replacement no longer works
Vutrisiran (Amvuttra)
RNA-silencing medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Transthyretin amyloidosis affecting the nerves or the heart
Plozasiran (Redemplo)
RNA-silencing medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Triglycerides